Guru Subramanian Guru Murthy1, Ehab Atallah2. 1. Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. gmurthy@mcw.edu. 2. Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
PURPOSE OF REVIEW: Chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI) have near-normal life expectancy. However, lifelong TKI therapy is associated with reduced quality of life and significant economic burden. Currently, the management of CML is shifting from continuous TKI therapy towards the goal of TKI cessation which is discussed in this review. RECENT FINDINGS: Several studies in the last decade have demonstrated the feasibility and safety of TKI discontinuation in selected patients with CML who achieve deep and sustained molecular response with TKI. This has moved prime-time into clinical practice although open questions remain in terms of understanding the disease biology that leads to successful TKI cessation in some patients while not in others. Cessation of TKI for CML patients is a feasible approach. Ongoing research aims to find out optimal strategies to sustain ongoing treatment-free remission (TFR) and increase the number of patients who achieve TFR.
PURPOSE OF REVIEW: Chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI) have near-normal life expectancy. However, lifelong TKI therapy is associated with reduced quality of life and significant economic burden. Currently, the management of CML is shifting from continuous TKI therapy towards the goal of TKI cessation which is discussed in this review. RECENT FINDINGS: Several studies in the last decade have demonstrated the feasibility and safety of TKI discontinuation in selected patients with CML who achieve deep and sustained molecular response with TKI. This has moved prime-time into clinical practice although open questions remain in terms of understanding the disease biology that leads to successful TKI cessation in some patients while not in others. Cessation of TKI for CMLpatients is a feasible approach. Ongoing research aims to find out optimal strategies to sustain ongoing treatment-free remission (TFR) and increase the number of patients who achieve TFR.
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: A Hochhaus; T Masszi; F J Giles; J P Radich; D M Ross; M T Gómez Casares; A Hellmann; J Stentoft; E Conneally; V García-Gutiérrez; N Gattermann; W Wiktor-Jedrzejczak; P D le Coutre; B Martino; S Saussele; H D Menssen; W Deng; N Krunic; V Bedoucha; G Saglio Journal: Leukemia Date: 2017-02-20 Impact factor: 11.528
Authors: Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Irina Dyagil; Nataliia Glushko; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Laurence Reilly; Allison Jeynes-Ellis; Eric Leip; Nathalie Bardy-Bouxin; Andreas Hochhaus; Tim H Brümmendorf Journal: J Clin Oncol Date: 2017-11-01 Impact factor: 50.717
Authors: William V Padula; Richard A Larson; Stacie B Dusetzina; Jane F Apperley; Rudiger Hehlmann; Michele Baccarani; Ekkehard Eigendorff; Joelle Guilhot; Francois Guilhot; Rudiger Hehlmann; Francois-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Susanne Saussele; Charles A Schiffer; Richard T Silver; Bengt Simonsson; Rena M Conti Journal: J Natl Cancer Inst Date: 2016-03-04 Impact factor: 13.506